Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression

J Thorac Oncol. 2019 Sep;14(9):e205-e206. doi: 10.1016/j.jtho.2019.04.023.

Authors

Brady Anderson¹, David E Dawe²

Affiliations

¹ Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
² Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada. Electronic address: ddawe@cancercare.mb.ca.

PMID: 31445738
DOI: 10.1016/j.jtho.2019.04.023

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Cholangitis, Sclerosing / chemically induced*
Humans
Immunosuppression Therapy / adverse effects
Immunosuppression Therapy / methods
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Male
Neoplasm Staging
Nivolumab / adverse effects*
Nivolumab / therapeutic use

Substances

Antineoplastic Agents, Immunological
Nivolumab